Clinical trials: Amyotrophic Lateral Sclerosis, open to volunteers
Amyotrophic Lateral Sclerosis
Development of Targeted RNA-Seq for Amyotrophic Lateral Sclerosis Diagnosis
Genetic diagnosis of Amyotrophic Lateral Sclerosis (ALS) could identify the origin of the disease, potentially allowing the patient to pursue targeted/gene therapy.
- Trial name
- ROSA (NCT06083584)
- Testing
- RNA sequencing
- Where
- 7 sites in France
- Volunteers
- 192 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis)
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
- Conditions
- Neurological Disorder, ALS (Amyotrophic Lateral Sclerosis), Motor Neuron Disease, ALS - Amyotrophic Lateral Sclerosis
- Trial name
- NCT07543367
- Testing
- Stentrode
- Where
- 5 sites in United States
- Volunteers
- 10 people
- Sponsor
- Synchron, Inc.
ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
The goal of this clinical trial is to learn whether a nasal spray medicine called foralumab is safe and easy to tolerate in adults with amyotrophic lateral sclerosis (ALS).
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis, ALS
- Trial name
- BANYAN (NCT07688239)
- Testing
- Foralumab Nasal
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Tiziana Life Sciences LTD
Amyotrophic Lateral Sclerosis, Cytochrome P-450 Enzyme System
A Study of LY3873862 in Participants With Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS).
The main purpose of this study in participants with Sporadic or Familial Amyotrophic Lateral Sclerosis (ALS) is to test the safety of different doses and to determine the amount of LY3873862 that gets into the bloodstream and how…
- Trial name
- NCT07883590
- Testing
- LY3873862, CYP450 Drug Cocktail
- Where
- 4 sites in United States, Canada
- Volunteers
- 32 people
- Sponsor
- Eli Lilly and Company
Amyotrophic Lateral Sclerosis
A Study to Learn About the Safety of BIIB147 and Its Effects in Adults With Amyotrophic Lateral Sclerosis (ALS)
In this study, researchers will learn more about the effects of BIIB147, in participants with amyotrophic lateral sclerosis, also known as ALS.
- Trial name
- HORIZON (NCT07855211)
- Testing
- BIIB147
- Where
- 2 sites in United States
- Volunteers
- 69 people
- Sponsor
- Biogen
Frontotemporal Dementia, Amyotrophic Lateral Sclerosis
Investigating Complex Neurodegenerative Disorders Related to Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Background: Neurodegenerative disorders can lead to problems in movement or memory. Some can cause abnormal proteins to build up in brain cells.
- Conditions
- Frontotemporal Dementia, Amyotrophic Lateral Sclerosis, Progressive Supranuclear Palsy
- Trial name
- NCT03225144
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Amyotrophic Lateral Sclerosis
Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS
PIONEER-ALS is a Phase 1/2, multicenter, open-label, ascending dose, uncontrolled, first-in-human study that will evaluate the safety, tolerability and effects on clinical and biomarker endpoints of intracisternal administration…
- Trial name
- ALS (NCT07287397)
- Testing
- VTx-002, Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone
- Where
- 11 sites in United States, Belgium and 2 more
- Volunteers
- 36 people
- Sponsor
- Vector Y Therapeutics
Amyotrophic Lateral Sclerosis
Brain-Computer Interface Communication Device for People With ALS
This study compares a wearable brain-computer interface (BCI) communication device with the eye-tracking communication devices that people with ALS already use.
- Trial name
- NCT07871071
- Testing
- Cognixion ONE AR-BCI configuration, Cognixion ONE screen-based BCI configuration, Existing eye-gaze speech generating device
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Cognixion
Amyotrophic Lateral Sclerosis (ALS)
Safety, Tolerability, and Pharmacodynamic Exploration of Orelabrutinib in Patients With Amyotrophic Lateral Sclerosis (ALS)
This is a single-center, open-label, dose-escalation, investigator-initiated pilot study to evaluate the safety, tolerability, dose-limiting toxicity (DLT), and pharmacodynamic signals of orelabrutinib in patients with…
- Trial name
- NCT07875972
- Testing
- Orelabrutinib
- Volunteers
- 12 people
- Sponsor
- Liu Qing
Amyotrophic Lateral Sclerosis
FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS.
- Trial name
- FUNCtion ALS (NCT07674667)
- Testing
- TRCN-1023
- Where
- 6 sites in Germany, Netherlands and 1 more
- Volunteers
- 30 people
- Sponsor
- Trace Neuroscience, Inc.
Amyotrophic Lateral Sclerosis
A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes.
- Trial name
- NCT06249867
- Testing
- Darifenacin 7.5 MG Extended Release Oral Tablet
- Where
- 2 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Oliver Blanchard
Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS)
Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
The goal of this clinical trial is to evaluate the safety and preliminary efficacy of an implantable device that records and stimulates different areas of the brain to allow adults affected by disabling paralysis (see Eligibility…
- Conditions
- Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS), Muscular Disorders, Atrophic, Brain Stem Stroke
- Trial name
- INTENT (NCT07521930)
- Testing
- INTENT Neural Interface System
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Johns Hopkins University
Amyotrophic Lateral Sclerosis (ALS)
Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?
Amyotrophic lateral sclerosis (ALS) is a fatal, rare neurodegenerative disease affecting 30,000 people in the United States. The gold standard of care for people with ALS is multidisciplinary clinics (MDC).
- Trial name
- VITALS (NCT07454733)
- Testing
- Video recording, Notes Instruction
- Where
- 7 sites in United States
- Volunteers
- 800 people
- Sponsor
- Trustees of Dartmouth College
Stroke, Parkinson Disease
PhiCube for Bilateral Upper Limb Neuromotor and Cognitive Rehabilitation in Adults
This randomized controlled pilot trial evaluates the usability and safety of PhiCube, a compact, portable, bilateral end-effector robotic device for upper limb rehabilitation, and its impact on motor and cognitive function.
- Conditions
- Stroke, Parkinson Disease, Amyotrophic Lateral Sclerosis, Spinal Cord Injuries
- Trial name
- PhiCube-Adults (NCT07865260)
- Testing
- PhiCube, Conventional rehabilitation
- Where
- 4 sites in Italy
- Volunteers
- 80 people
- Sponsor
- Istituto di Sistemi e Tecnologie Industriali Intelligenti per il Manifatturiero Avanzato
Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American…
- Conditions
- Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD)
- Trial name
- NCT04363684
- Where
- 26 sites in United States, Canada
- Volunteers
- 2,100 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Amyotrophic Lateral Sclerosis
Trial on the Biological and Clinical Effects of Acetyl-L-carnitine in ALS
Phase II/III multicenter, randomized, double-blind, placebo-controlled trial on acetyl-L-carnitine (ALCAR) in subjects living with amyotrophic lateral sclerosis (ALS).
- Trial name
- ALCALS (NCT06126315)
- Testing
- Acetyl-l-carnitine
- Where
- 19 sites in Australia, Italy
- Volunteers
- 246 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine.
- Trial name
- PREVAiLS (NCT07322003)
- Testing
- Pridopidine
- Where
- 55 sites in United States, Belgium and 11 more
- Volunteers
- 500 people
- Sponsor
- Prilenia
Amyotrophic Lateral Sclerosis
TP04HN106 in the Treatment of Patients With Amyotrophic Lateral Sclerosis
This trial adopts a multicenter, randomized, double-blind, placebo-controlled parallel design. This experiment is divided into two groups: the experimental drug group and the placebo group.
- Trial name
- NCT06726577
- Testing
- TP04HN106, Saline
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Talengen Institute of Life Sciences, Shenzhen, P.R. China.
Paralysis; Quadriplegic, Quadraplegia
MindEx: A Novel, Multifocal, Cognitive Brain-Machine Interface System
This research study is being done to develop a novel brain-computer interface (BCI) technology that can enable severely paralyzed individuals to interact with the world through direct brain-control of a computer.
- Conditions
- Paralysis; Quadriplegic, Quadraplegia, Tetraplegia, Tetraplegic Motor Dysfunction Following Brainstem or Spinal Cord Injury
- Trial name
- NCT05936619
- Testing
- Mind Extender (MindEx)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Nader Pouratian
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)
Background: Amyotrophic lateral sclerosis (ALS) is a disorder that damages nerve cells in the brain and spinal cord. It can cause muscle weakness, paralysis, and loss of movement. The symptoms grow worse over time.
- Trial name
- NCT07204977
- Testing
- Acamprosate calcium
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)